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Objectives: To assess pill burden, health care resource utilization (HRU), and costs 
among patients with long-term immediate release (IR) hydrocodone use. MethOds: 
We performed a retrospective analysis of health care claims from 2011-2012 Truven 
MarketScan® Commercial, Medicare supplemental, and Medicaid Multistate data-
bases. Patients with IR hydrocodone prescription for ≥ 90 days during 6 month 
baseline period (July 2011- December 2011) with continuous enrollment during 
baseline and 12 month follow-up periods were selected. The final population was 
sub-categorized by prescribed coverage days (PCD) of IR hydrocodone during base-
line into 90-119, 120-179, and ≥ 180 days. Chi-square or ANOVA analyses were used to 
test pill burden, HRU and costs (standardized to 2013 US dollars) during baseline and 
follow-up periods across subpopulations. Results: A total of 36,174 commercial, 
32,699 Medicaid, and 8,873 Medicare IR hydrocodone users were selected. In the 
baseline period, subgroups with longer PCD had significantly more average hydroco-
done pills per month yet fewer HRU and medical costs (all p< 0.05). However, during 
the follow-up period, groups with longer PCD had greater increase in number of 
inpatient hospitalizations and other types of HRU (length of stay, outpatient hospital 
visits, office visits, and emergency room visits). The subgroup of patients with PCD 
< 120 days had lower annual all-cause medical costs during follow-up compared 
with baseline (decreasing $2,624, $2,955, $4,209 per patient per year in Medicaid, 
Medicare and commercial patients, respectively), while patients with longer PCD 
during baseline had increased costs (p< 0.05). For example, Medicaid patients with 
120-179 PCD had an increase of $1,874 and those with ≥ 180 PCD had an increase of 
$4,348. These trends were similar for all insurance types. cOnclusiOns: Extended 
length of PCD, particularly after 120 days, corresponds with higher patient burden 
including elevated pill burden and rising HRU and costs in both commercial and 
public insurance patients with long-term IR hydrocodone use.
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Objectives: Although acromegaly is acknowledged as requiring resource-intensive 
treatment, its ultimate economic burden is unclear. As an extension of work pre-
sented at ISPOR 2013 International Conference (New Orleans, US), the objective of 
this research is to measure the annual economic burden of acromegaly in France 
using a case-review methodology with a prevalence-based sample of patients diag-
nosed with acromegaly. MethOds: A case-review method was used with a sample 
of 22 endocrinologists reviewing 88 patient cases (4 cases per physician) diagnosed 
with acromegaly. The patient case histories included: resource utilization includ-
ing office visits and hospitalization, diagnostic procedures and labs, medications 
prescribed, medical procedures preformed, and an estimate of lost productivity. A 
micro-costing analysis was conducted to obtain costs in the prior 12 months for 
each patient case reviewed using published literature, medical fee schedules, and 
pharmaceutical cost databases to assign costs to treatments and medical proce-
dures identified in the survey data. Annual costs were examined across a broad 
range of patients of different ages, gender and time from diagnosis. Two biomarkers 
were used to categorize acromegaly patients as Controlled vs. Uncontrolled: Insulin 
Growth Factor-1 (IGF-1) and Growth Hormone (GH). Several patient characteristics 
were used as control factors when comparing annual economic costs: age, sex, 
and time from diagnosis. Statistical tests and confidence intervals were calcu-
lated to determine the significance of patient characteristic effects on economic 
burden. Results: Three patient subgroups were used to classify uncontrolled 
acromegaly patients: IGF-1, GH and both IGF-1 and GH. The annual per-patient 
economic burden of disease costs ranges from € 29,000 to € 79,400 across these 
groups. These cost ranges are benchmarked to other studies to provide context 
and validity. cOnclusiOns: The total economic burden of acromegaly in France 
is significant. Understanding the factors impacting burden of illness will inform 
future improvements in treatment practice.
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Objectives: To estimate rates of diagnosed abuse and incremental health care 
costs among long-term immediate release (IR) hydrocodone users. MethOds: We 
performed a retrospective analysis of health care claims from 2011-2012 Truven 
MarketScan® Commercial and Medicaid Multistate databases. Patients with IR 
hydrocodone prescription ≥ 90 days during 6 month baseline period (July 2011- 
December 2011) with continuous enrollment during baseline and 12 month follow 
up periods were selected. Opioid abuse was defined as a patient having at least 
one medical claim indicating opioid abuse/dependency (ICD-9-CM diagnosis codes: 
304.0x, 304.7x, 305.5x, 965.00,965.02 or 965.09) during the study period. Rates of 
opioid abuse during baseline and follow up periods were estimated by plan type, 
along with total health care costs, standardized to 2013 US dollars. Generalized 
linear model regressions were used to estimate incremental costs in the post-index 
period. Results: A total of 32,699 Medicaid and 36,174 commercial IR hydrocodone 
users were selected in the study. Rates of abuse were 96 and 36 per 10,000 patients, 
respectively. Abusers had higher unadjusted annual total health care costs than 
non-abusers during both baseline and follow up period (p< 0.05). After controlling 
for baseline characteristics of age, gender, Charlson Comorbidity Index, pill burden 
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Mepact® (mifamurtide) is the first drug approved for treatment of high-grade resect-
able non-metastatic osteosarcoma in patients aged 2-30 in the last 20 years. It 
follows a randomised clinical trial showing a statistically-significant and clinically-
relevant decrease in the risk of death without compromising safety. Objectives: 
This study assessed the cost-effectiveness and budget impact of mifamurtide added 
to the standard chemotherapy of cisplatin, doxorubicin and methotrexate with 
this same standard therapy (ST) without mifamurtide. MethOds: A Markov model 
was built to combine trial-based outcomes with Spanish resource use and unit 
cost of compared options. The analysis has been carried out from the perspective 
of the Spanish National Health Service, with a time horizon of up to 60 years in 
the base analysis. A probabilistic sensitivity analysis was carried out to assess the 
influence of the uncertainty of the variables introduced into the model. All the 
costs are expressed in euros for the year 2011 and, beyond the first year, both costs 
and effects (quality-adjusted survival) have been discounted with an annual rate 
of 3%, following local recommendations. Results: The observed greater efﬁcacy 
of mifamurtide in the trial translates into a gain of 3.03 (undiscounted) and 1.33 
(discounted) QALYs and an additional cost of € 102,000. The estimated budgetary 
impact of using mifamurtide in 10% to 100% of the potential population would cost 
€ 671,000 and € 6.7 million respectively. cOnclusiOns: The iCER of mifamurtide in 
Spain is in the low band (< € 100,000) of the iCERs obtained by other orphan drugs 
and would have a limited, predictable and affordable cost in Spain.
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Objectives: To evaluate and compare costs of belimumab treatment plus stand-
ard of care (SoC) vs SoC alone in patients with systemic lupus erythematosus 
(SLE). MethOds: The cost analysis was conducted of the belimumab treatment plus 
SoC vs SoC alone for one year. Based on the results of clinical trials to assess safety 
and efficacy of belimumab (BLISS-52 and BLISS-76) the cost structure of treatment was 
determined. Results: The costs were evaluated in the following groups: drug costs, 
costs of inpatient and outpatient visits, costs for correction of adverse events and 
costs for treating of SLE complications. The costs of inpatient visits comprised 91,830 
RUB/ 1,976 EUR for SoC alone and 52,991 RUB/ 1,140 EUR for patients treated with 
belimumab plus SoC. The correction of adverse events came to 7,763 RUB/ 167 EUR for 
SoC alone, while for belimumab plus SoC it was 7,846 RUB/ 169 EUR. The costs of treat-
ing SLE complications totaled 384,976 RUB/ 8,283 EUR and 370,229 RUB/ 7,966 EUR for 
SoC alone and belimumab plus SoC groups of patients, respectively. cOnclusiOns: 
The costs of inpatient visits in belimumab treatment group were lower than those of 
the SoC group resulting from a reduction in the frequency of SLE flare. The costs for 
correction of adverse events were similar in both patients groups due to a good safety 
profile of belimumab. The level of costs for treating SLE complications was lower in 
belimumab as compared to that in SoC group as a consequence of lower frequency of 
cardiovascular, pulmonary, renal, and skin complications in the belimumab treatment 
group. A good safety profile and efficacy of belimumab, which had been demonstrated 
in clinical trials, led to a decrease in costs of inpatient visits and treatment of SLE 
complication in patients treated with belimumab.
PSY34
oPioid PreScriBing and the iMPact of Branded genericS
Truter I.
Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
Objectives: Opioids are the mainstay of therapy for patients with moderate to 
severe pain. Mandatory generic substitution exists in South Africa, unless other-
wise indicated by the prescriber or if the patient refuses. Few studies have been 
conducted in South Africa analysing the prescribing patterns and cost of opioid 
analgesics. MethOds: A retrospective, cross-sectional drug utilisation study was 
conducted on prescription data of a medical insurance scheme administrator 
in South Africa for 2011. The database contained 2 298 312 records for medicine, 
medical devices and procedures. Results: A total of 97 491 analgesics were dis-
pensed to 31 854 patients during the year. Within ATC category N02, opioids (NO2A) 
accounted for 26.55% of analgesic prescriptions at a cost of R1 071 230.14. A total of 
9 793 patients were prescribed 25 888 opioid analgesics. The average age of patients 
was 41.50 (SD= 16.61) years. Female patients were slightly younger (average age: 
40.69 (SD= 17.05) years) than male patients (average age: 42.32 (SD= 16.09) years). 
Nine different active ingredients and two combination products were prescribed. 
Tramadol, an atypical opioid, was the most often prescribed (68.11%), followed by 
pethidine (14.39%) and morphine (8.38%). The average cost per prescription was 
R41.38 (SD= R69.29). Fentanyl had the highest average cost per prescription (R454.43), 
and pethidine the lowest (R8.53). Overall, the average cost for an originator product 
was R56.25 and for a generic product R28.95. Tramadol accounted for 68.11% of 
prescriptions and 80.40% of cost. Tramadol had the most most branded generic 
equivalents on the market (7), yet only had 42.89% generic prescribing. Most pre-
scriptions were issued by private hospitals (62.89%), followed by pharmacies (24.41%) 
and general medical practices (12.16%). Only 35.48% of the products were prescribed 
on a chronic basis. cOnclusiOns: Tramadol dominated opioid prescribing. The 
study confirmed price differences for opioid analgesics between branded generics 
and originator products.
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